Insulet stock crashed Wednesday after lowering sales guidance for its body-worn insulin pump in the back half of the year.
These Two Medical Stocks Are Screaming Sell — Here's What Happened
Licensing
Insulet (PODD) stock crashed Wednesday — alongside fellow medtech Medline (MDLN) — after lowering sales guidance for its body-worn insulin pump, Omnipod, in the back half of the year. The company now expects sales to grow 20% to 22% this year, in constant currency, down from its prior view for 21%-23% growth. On a reported based, Insulet projects sales growth…
Insulet (PODD) stock falls despite beating Q2 earnings as the company lowers its full-year 2026 revenue guidance. Get details…
Insulet Corp. (NASDAQ:PODD) reported strong Q2 earnings but lowered revenue outlook for 2021. Analysts downgraded stock and…
PODD Fraud Alert: Insulet Corporation Sued for Securities Fraud after Safety Issues Lead to a 6% Stock Drop – Investors Notified…
PODD Lawsuit Notice: Insulet Safety Issues and 6% Stock Drop Trigger Securities Fraud Class Action
FDA classified Insulet's Omnipod pod recall as Class I after reports of insulin under-delivery linked to 24 serious injuries.
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Insulet Corporation (PODD) Shareholders To…
PODD INVESTOR REMINDER: Insulet Corporation Investors Have Until August 31, 2026 To Seek Lead Plaintiff Role
